

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

-----  
In re Application of:  
**Michael Clandinin**

Serial No.: **10/551,789**

Filed: July 5, 2006

For: **FORMULATIONS FOR  
MEDIATING INFLAMMATION  
AND FOR REDUCING BLOOD  
CHOLESTEROL**  
-----

Attorney Docket No. **D4858-00059**

Confirmation No: **3396**

Group Art Unit: **1623**

Examiner: **Eric Olson**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT TRANSMITTAL LETTER**

Dear Sir:

Enclosed herewith is an Information Disclosure Statement pursuant to 37 CFR § 1.56 in connection with the above-identified application. This information disclosure statement is being filed to bring to the attention of the examiner references that have been cited in pending related U.S. Patent Application No. 11/662,858, and that have not already been made of record in the above-identified application.

The Commissioner is hereby authorized to charge the fee of **\$180.00**, due with this submission, as well as any other required fees to Deposit Account No. **04-1679**.

Respectfully submitted,

DATE: May 6, 2009

/Robert M. Gould/  
Robert M. Gould, Esquire  
Reg. No. 43,642

**DUANE MORRIS LLP**  
120 S. LaSalle Street, Suite 3700  
Chicago, Illinois 60602  
Telephone (312) 499-6706  
Facsimile (312) 277-9439